Embolic Acceleration, LLC.

We would like to introduce the HourGlass™, a 510(k) cleared and CE marked, commercialization-ready, innovative embolization and occlusion system developed by Embolic Acceleration, LLC for the treatment of trauma, cancer, and vascular anomalies.

Embolization and occlusion are the catheter-delivered management of vascular blood flow to achieve therapeutic objectives. Vascular anomalies, trauma, and cancer represent just three patient conditions that commonly require the permanent "shut off" of blood flow. To treat these conditions, our innovative HourGlass™ platform uses minimally invasive techniques similar to the access, guide wires and catheters used in more familiar procedures such as angioplasty and stenting. HourGlass™ intends to replace and supplant the traditional plugs and coils currently used in most embolization and occlusion procedures performed today.

Catheter-based occlusion procedures are routinely performed in the hospital and office-based catheter labs by Interventional Radiologists (IR's). The overall occlusion market exceeds $3B globally. The available plug/coil market for conventional occlusion in the peripheral vascular system approaches $276M (5.9% CAGR) in the United States and Western Europe.

Pivoting to cancer treatment, catheter-based delivery of embolic agents such as radioactive particles and chemo drug eluting microspheres for the treatment of tumors represents an additional $258M in TAM. HourGlass™ is the only device that combines conventional occlusion with the ability to deliver embolic agents. Extensive clinical feedback for both conventional occlusion and delivery of embolic agents have resulted in the HourGlass™ platform which addresses existing unmet needs while reducing the cost of the occlusion.

To date, we have achieved significant development milestones. Among them are: secured CE Mark for use in 3mm-8mm vessels in Europe and 510(k) clearance for 6mm-8mm vessels in the US; completed a 50-patient human-use study; obtained strong intellectual property protections, including several issued patents; completed production readiness; and obtained ISO certification for our quality system and facility.

We are raising up to $15M in our Series C round to reach full commercialization of the HourGlass™ to include the following items: execute our US test territory launch, expand the vessel range in the US to match our CE Mark, manufacturing scale up, cost reduction, and expand our US sales force to achieve a significant revenue target in 2023 to unlock a significantly higher valuation. These funds will also be directed to obtain oncology-specific indications on the current product line to expand the current addressable market further. Additionally, we will continue to explore and engage in M&A discussions with medical device companies in parallel with the activities listed above.

The company is headquartered in Miramar, Florida and utilizes the expansive services of Naglreiter Medical Device Development Organization (NMDDO) including its 17,000 sqft facility and over 100 associate medical device professionals. NMDDO is a novel, "fractional" incubator with a track record of device development and successful exits at a fraction of traditional development costs.